A second phase III study to evaluate the efficacy and safety of multiple intravitreal (IVT) injections of APL-2 in patients with Geographic Atrophy (GA).

Trial Profile

A second phase III study to evaluate the efficacy and safety of multiple intravitreal (IVT) injections of APL-2 in patients with Geographic Atrophy (GA).

Planning
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs APL 2 (Primary)
  • Indications Age-related macular degeneration; Dry macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Dec 2017 New trial record
    • 20 Dec 2017 According to a Apellis Pharmaceuticals media release, US FDA has finalized the trial design for Phase 3 program, which contains two identical phase III clinical trials of APL-2 to treat patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top